Navigation Links
Genetic Engineering & Biotechnology News reports on cancer biomarkers
Date:4/1/2008

New Rochelle, NY, April 1, 2008Biotechnology companies are focusing on the development of novel biomarkers to overcome the limitations of current diagnostic tests for cancer, reports Genetic Engineering and Biotechnology News (GEN). To effectively move cancer therapy forward, a much stronger and targeted emphasis on diagnosis will be required, according to an article in the April 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2428).

"Therapeutic protocols can involve hundreds of thousands of dollars per cancer patient," notes John Sterling, Editor-in-Chief of GEN (www.genengnews). "Coming up with effective and validated biomarkers that detect cancer while still in its early stages seems like an extremely worthwhile effort on which to spend R&D funds now to cut down on costs of treatment in the future."

A team led by Edouard Nice, Ph.D., at the Ludwig Institute for Cancer Research, is one example of a group hard at work trying to develop early detection tools for malignancies. Dr. Nice and his colleagues are using multidimensional high-performance liquid chromatography to trace enrich low-level components such as growth factors in tumor material prior to analysis by mass spectrometry.

At Wayne State University School of Medicine, a research program run by Michael Tainsky, Ph.D., harnesses antibodies in patients' serum for the detection of cancer-specific epitopes using peptides selected for IgG binding from phage-display cDNA libraries.

Other biomarker-related projects covered in the GEN article include those at Sienna Cancer Diagnostics, Geron, Quest Diagnostics Nichols Institute, Gentel Biosciences, Celera, University of Washington, Abbott Laboratories, Strategic Diagnostics, Plasma Proteome Institute, and Biosite.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use fingerprints instead ... National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in ... the boarding process to allow eligible Delta SkyMiles Members who are enrolled ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology: